{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035223","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.909889+00:00","generated_at":"2026-05-31T12:12:50.142005+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aquestive Q2 revenue up 52% to $20.1M; narrows net loss; raises FY guidance","bullets":["Total revenue $20.1M vs $13.2M YoY; net loss $2.7M ($0.03/sh) improves from $5.8M loss.","Non-GAAP adjusted EBITDA positive $1.8M vs -$3.3M; cash $89.9M.","Raises FY24 revenue guidance to $57-60M (prev. $48-51M); adj. EBITDA loss guidance narrowed to $20-23M.","Anaphylm NDA submission on track for Q1 2025; launch expected end 2025/early 2026.","Libervant expanded to ages 2-5; national retail distribution expected Q4 2024; epinephrine prodrug investor day planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035223","json":"https://secwatch.observer/filing/0001628280-24-035223.json","markdown":"https://secwatch.observer/filing/0001628280-24-035223.md","text":"https://secwatch.observer/filing/0001628280-24-035223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024035223/0001628280-24-035223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024035223/aqst-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:12:50.142005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}